Centene Corporation은 미국에서 보험이 충분하지 않은 가정과 상업 조직을 대상으로 프로그램과 서비스를 제공하는 관리형 진료(Managed Care) 회사로 운영됩니다. 회사는 메디케이드, 메디케어, 커머셜, ...
웰스 파고는 센텐(CNC)에 대해 '매수등급(Equal-Weight)'을 유지하면서 목표주가를 69.00달러로 상향했으며, 이는 23.21%의 상승입니다. GuruFocus 데이터에 따르면 CNC는 GF Value™가 83.37달러로, 18.0% 저평가되어 있는 것으로 보입니다. 다만 최근 3개월 동안 내부자 매도는 총 520만 달러에 달했습니다. 회사의 GF Score™는 100점 만점에 73점으로, 높은 수익성과 밸류에이션은 강점인 반면 성장성은 약한 점을 보여줍니다.
BioMarin은 FDA가 VOXZOGO의 보충적 신약 허가 신청(sNDA)을 접수했으며, 아콘드로플라시아에 대해 2027년 2월 28일까지 완전 승인을 목표로 하고 있다고 발표했습니다. 이번 신청은 진행 중인 3개의 연구에서 축적된 광범위한 장기 안전성 및 유효성 데이터에 의해 뒷받침되며, 어린이의 골격 성장에서 유의미한 개선이 확인됐습니다. 완전 승인은 VOXZOGO의 시장 도달 범위를 넓혀, 전 세계 수요를 충족하고 BioMarin의 매출 잠재력을 강화하는 한편, 희귀 질환 치료 분야에서의 리더십을 공고히 할 것으로 예상됩니다.
센텐 코퍼레이션(ISIN US15133V1035)은 메디케이드와 메디케어 같은 정부 지원 건강보험 프로그램에 집중하는 미국의 주요 관리형 케어(Managed-care) 기업입니다. 회사의 실적은 미국 헬스케어 정책, 규제 변화, 환급(리임버스먼트) 흐름에 크게 영향을 받으며, 이러한 요인들이 장기 투자 서사의 핵심이 됩니다. 센텐의 비즈니스 모델은 다양한 인구 집단을 대상으로 건강 혜택을 관리·운영하는 것으로, 성공은 효과적인 의료비 관리, 엄격한 언더라이팅, 전략적 운영 다각화에 달려 있습니다.
센텐 코퍼레이션의 자회사인 Meridian Health Plan of Illinois는 일리노이 주의 HealthChoice Illinois 메디케이드 프로그램에 따라, 2027년 1월 1일부터 2030년까지 4년간 계약 갱신을 확보했습니다. 이번 갱신은 단기 실적을 크게 끌어올릴 것으로 예상되지는 않지만, 정부 지원 의료 프로그램에 대한 의존도를 고려할 때 프리미엄 매출을 유지하고 센텐의 장기 실적 가시성을 높이는 데 중요합니다. 회사 주가는 연초 이후 64.3% 상승하며 업계를 상회했으며, 2026년 이익은 66.4% 성장할 것으로 전망됩니다.
Centene Corporation은 2026년 7월 28일 화요일 오전 약 6:00(ET)에 Q2FY26 재무 실적을 발표할 예정이며, 이후 오전 8:30(ET)에 실적을 논의하기 위한 컨퍼런스 콜을 진행한다고 발표했습니다. 투자자 및 관심 있는 분들은 다이얼인 번호 또는 회사 웹사이트를 통해 제공되는 라이브 오디오 웹캐스트로 콜에 접속할 수 있습니다. Fortune 500 헬스케어 기업인 Centene은 메디케이드, 메디케어, 건강보험 마켓플레이스(Health Insurance Marketplace) 회원들에게 서비스를 제공합니다.
웰스 파고는 센텐(CNC)에 대해 '매수등급(Equal-Weight)'을 유지하면서 목표주가를 69.00달러로 상향했으며, 이는 23.21%의 상승입니다. GuruFocus 데이터에 따르면 CNC는 GF Value™가 83.37달러로, 18.0% 저평가되어 있는 것으로 보입니다. 다만 최근 3개월 동안 내부자 매도는 총 520만 달러에 달했습니다. 회사의 GF Score™는 100점 만점에 73점으로, 높은 수익성과 밸류에이션은 강점인 반면 성장성은 약한 점을 보여줍니다.
BioMarin은 FDA가 VOXZOGO의 보충적 신약 허가 신청(sNDA)을 접수했으며, 아콘드로플라시아에 대해 2027년 2월 28일까지 완전 승인을 목표로 하고 있다고 발표했습니다. 이번 신청은 진행 중인 3개의 연구에서 축적된 광범위한 장기 안전성 및 유효성 데이터에 의해 뒷받침되며, 어린이의 골격 성장에서 유의미한 개선이 확인됐습니다. 완전 승인은 VOXZOGO의 시장 도달 범위를 넓혀, 전 세계 수요를 충족하고 BioMarin의 매출 잠재력을 강화하는 한편, 희귀 질환 치료 분야에서의 리더십을 공고히 할 것으로 예상됩니다.
센텐 코퍼레이션(ISIN US15133V1035)은 메디케이드와 메디케어 같은 정부 지원 건강보험 프로그램에 집중하는 미국의 주요 관리형 케어(Managed-care) 기업입니다. 회사의 실적은 미국 헬스케어 정책, 규제 변화, 환급(리임버스먼트) 흐름에 크게 영향을 받으며, 이러한 요인들이 장기 투자 서사의 핵심이 됩니다. 센텐의 비즈니스 모델은 다양한 인구 집단을 대상으로 건강 혜택을 관리·운영하는 것으로, 성공은 효과적인 의료비 관리, 엄격한 언더라이팅, 전략적 운영 다각화에 달려 있습니다.
센텐 코퍼레이션의 자회사인 Meridian Health Plan of Illinois는 일리노이 주의 HealthChoice Illinois 메디케이드 프로그램에 따라, 2027년 1월 1일부터 2030년까지 4년간 계약 갱신을 확보했습니다. 이번 갱신은 단기 실적을 크게 끌어올릴 것으로 예상되지는 않지만, 정부 지원 의료 프로그램에 대한 의존도를 고려할 때 프리미엄 매출을 유지하고 센텐의 장기 실적 가시성을 높이는 데 중요합니다. 회사 주가는 연초 이후 64.3% 상승하며 업계를 상회했으며, 2026년 이익은 66.4% 성장할 것으로 전망됩니다.
Centene Corporation은 2026년 7월 28일 화요일 오전 약 6:00(ET)에 Q2FY26 재무 실적을 발표할 예정이며, 이후 오전 8:30(ET)에 실적을 논의하기 위한 컨퍼런스 콜을 진행한다고 발표했습니다. 투자자 및 관심 있는 분들은 다이얼인 번호 또는 회사 웹사이트를 통해 제공되는 라이브 오디오 웹캐스트로 콜에 접속할 수 있습니다. Fortune 500 헬스케어 기업인 Centene은 메디케이드, 메디케어, 건강보험 마켓플레이스(Health Insurance Marketplace) 회원들에게 서비스를 제공합니다.
Centene Corp.는 메디케이드와 ACA 마켓플레이스 같은 정부 지원 프로그램에 중점을 둔 미국의 주요 관리의료(Managed Care) 플레이어로, 특화 서비스도 함께 제공합니다. 이 다각화된 모델은 이러한 각 부문 전반에서의 성장을 균형 있게 뒷받침하며, 의료비용 추세에 대한 세심한 관리와 규제 준수가 요구됩니다. 회사의 전략은 계약 유지, 신규 주로의 확장, 안정적인 등록과 예측 가능한 의료 비용을 보장하기 위한 효율적인 급여(benefit) 설계에 초점을 맞추고 있습니다.
Barclays는 Agilon Health(AGL)에 대한 Hold 등급을 재확인하며 목표주가를 81.00달러로 설정했습니다. 애널리스트 Andrew Mok CFA는 헬스케어 부문을 담당하며 성공률은 51.86%입니다. Agilon Health에 대한 더 넓은 애널리스트 컨센서스 역시 Hold이며, 평균 목표주가는 57.15달러입니다. 이는 회사의 최근 실적 보고서에서 분기 매출 14.2억 달러, 순이익 2,997만 달러를 기록한 데 따른 것입니다.
Old Republic International Corporation(NYSE: ORI)은 2026년 2분기 재무 실적을 2026년 7월 23일(목) 장 시작 전 발표할 것이라고 밝혔습니다. 회사는 같은 날(동부시간 기준) 오후 3:00에 실적을 논의하기 위한 실적 컨퍼런스 콜도 개최하며, 이 콜은 웹캐스트와 전화로 접속할 수 있습니다. 역사적으로는 실적 발표가 단기 주가의 부정적인 움직임을 초래하는 경우가 종종 있었던 반면, 콜 공지는 소폭의 긍정적인 반응을 보였습니다.
Centene Corporation's Illinois subsidiary, Meridian Health Plan of Illinois, Inc., has secured a four-year contract renewal to continue providing services for the HealthChoice Illinois Medicaid managed care program, starting January 1, 2027. The renewed contract highlights Meridian's strong local partnerships and commitment to delivering high-quality, coordinated care to approximately 2.4 million Medicaid-eligible residents. This news comes as Centene's stock has shown positive performance, trading near its 52-week high, and the company has received favorable analyst ratings and strategic board appointments.
Shares of Alignment Healthcare (NASDAQ:ALHC) dropped 16.7% after a former executive filed a whistleblower lawsuit, alleging the company misreported expenses to inflate profits. The suit claims that reclassifying certain expenses would turn a positive adjusted EBITDA for 2024 into a loss. Alignment Healthcare denies the allegations, stating an independent audit found no basis for the claims, and the company plans to vigorously defend itself.
Centene Corp, a major U.S. managed care company, is navigating ongoing shifts in government healthcare programs, particularly Medicaid and Medicare. Investors are closely monitoring how the company balances growth, reimbursement changes, and margin discipline in its core markets. Its financial performance is tied to member volume, the mix of enrollees, and medical cost trends, making margin management a key focus for its valuation.
Centene Corp. (CNC) shares rose 1.47% to $67.09 on Wednesday, outperforming the broader market, which saw the S&P 500 Index fall 0.28% and the Dow Jones Industrial Average fall 1.09%. This marks the company's second consecutive day of gains, despite an overall tough trading session.
UnitedHealth Group (UNH) is investing $1.5 billion in AI initiatives for 2026, aiming to integrate AI across all its operations, including insurance, pharmacy, and care delivery, to simplify healthcare processes and improve user experience. The company expects these investments to streamline prior authorizations, accelerate prescription approvals, and enhance clinical productivity, extending beyond mere cost savings to strengthen customer relationships and expand software revenue. While competitors like Humana and Centene also leverage AI for efficiency, UNH's comprehensive approach positions it to reinforce its competitive standing in the digital healthcare industry.
Centene Corp. continues to operate as a major U.S. managed care provider, offering Medicaid, Medicare, and marketplace plans. The company's revenue is largely derived from government-sponsored programs, with contract renewals influenced by quality metrics and cost management. Its presence in the Affordable Care Act marketplace is significant, attracting price-sensitive consumers, though profitability is subject to policy changes and regulatory requirements.
Centene Corp (CNC) currently exhibits a "Strong Buy" technical sentiment, based on an analysis of its moving averages and oscillators. The MACD indicator provides a Buy signal, and the stock is trading above its 60-day and 200-day moving averages. Key resistance is at $69.203 and support at $61.628, while the RSI suggests a neutral condition.
Centene Corp. will withdraw its participation in Arkansas' Medicaid expansion program (ARHOME) next year, affecting approximately one-third of the program's enrollees. The Department of Human Services will transfer these beneficiaries to other eligible plans, with no immediate action required by enrollees. This decision follows a drop in individual coverage enrollees through the Affordable Care Act and coincides with Arkansas implementing new Medicaid work requirements.
Health insurer Centene will cease its participation in Arkansas's Medicaid expansion program, ARHOME, beginning next year. This decision will affect approximately one-third of the program's 211,000 enrollees, who will be transferred to existing BlueCross Blue Shield plans. The withdrawal comes as Arkansas prepares to reinstate work requirements for Medicaid recipients starting in January.
Centene Corp., a major health insurer and parent company of three Arkansas health insurance plans, will cease participation in Arkansas's Medicaid expansion program, ARHOME, starting next year. This decision will impact about one-third of the more than 211,000 Arkansans currently enrolled in Centene plans (Ambetter, QCA Health Plan, and QualChoice Life and Health). The Department of Human Services (DHS) will transfer these enrollees to other eligible plans, with BlueCross BlueShield's three plans remaining in the program.
Centene Corp., the parent company of several Arkansas health insurance plans, will withdraw from the state's Medicaid expansion program (ARHOME) next year. This decision will impact about one-third of the over 211,000 Arkansans currently enrolled in Centene’s ARHOME plans, who will be transferred to other eligible plans. The state Department of Human Services will provide instructions to beneficiaries soon, while new work requirements for Medicaid recipients are set to be reinstated next year under the One Big Beautiful Bill Act.
Centene Corp., the parent company of several Arkansas health insurance plans, will withdraw from the state's Medicaid expansion program, ARHOME, starting next year. This decision will impact approximately one-third of the 211,000 Arkansans currently enrolled in Centene's three plans, who will be transferred to other eligible plans. The move comes as Arkansas prepares to reinstate work requirements for Medicaid recipients next year.
Cantor Fitzgerald maintained an "Overweight" rating for Centene Corporation (CNC) and raised its price target from $60.00 to $75.00, indicating increased confidence in the company. GuruFocus rates CNC as undervalued by 20.9% with a GF Value™ of $83.45 and a GF Score™ of 73/100, highlighting strong profitability and valuation. Despite this, insider activity shows $5.2 million in sales and a lower growth rank, suggesting investors should consider these factors.
UnitedHealth announced that an audit by FTI Consulting found nearly 97% of diagnoses made by its HouseCalls home-health unit in 2025 were supported by patient medical records. This comes after scrutiny from lawmakers and the Department of Health and Human Services regarding unsupported diagnoses impacting Medicare Advantage payments. The company acknowledges room for improvement in documentation practices.
Cantor Fitzgerald has increased its price target for Centene Corp. shares to $75 from $60, maintaining an Overweight rating, citing a favorable outlook for payors and continued strength in government insurance lines despite Medicaid concerns. Centene, trading at $66.05, is seen as undervalued by InvestingPro, with a Fair Value of $79.93. The firm highlighted Centene and UNH as top payor picks, with Centene set to report earnings on July 28th.
Cantor Fitzgerald has raised its price target for Centene Corp. (NYSE:CNC) shares to $75 from $60, maintaining an Overweight rating. This increase reflects a positive outlook on payors heading into the second quarter 2026 earnings season, despite concerns around Medicaid, with the firm noting encouraging commentary on value-based care. Centene, trading near
Centene Corp. is a major US managed care provider that focuses on government-sponsored healthcare programs like Medicaid, Medicare, and Affordable Care Act marketplaces. The company's business model involves coordinating care, managing medical costs, and providing access to healthcare networks for low-income and underserved populations. Centene's success is closely tied to policy decisions, regulatory changes, and efficient management of medical costs and membership dynamics, including Medicaid redeterminations.
Centene Corp., parent company of several Arkansas health insurance plans, will cease participation in the state's Medicaid expansion program, ARHOME, starting next year. This decision will affect approximately one-third of the more than 211,000 Arkansans currently enrolled in Centene's three plans, who will be transferred to other eligible plans. The change comes as Arkansas prepares to reinstate work requirements for Medicaid recipients under the One Big Beautiful Bill Act.
This July 2026 update details regulatory and legislative changes impacting several key areas. It covers developments in gender identity discrimination under the ACA, FLSA overtime exemption standards, the ERISA status of "Trump Accounts," and recent antitrust settlements for Blue Cross Blue Shield. The update also includes information on PCORI fee reporting, Massachusetts MCC standards for 2027, and mid-year increases in Paid Family and Medical Leave benefits in certain states.
Centene Corp., parent company of several Arkansas health insurance plans, will cease participation in the state's Medicaid expansion program, ARHOME, next year. This decision affects approximately one-third of the 211,000 Arkansans enrolled in ARHOME, who will be transferred to plans offered by BlueCross BlueShield. The change comes as Arkansas prepares to reinstate Medicaid work requirements under the One Big Beautiful Bill Act.
Centene Corp. will withdraw from Arkansas’ Medicaid expansion program, ARHOME, starting next year. This move will impact approximately one-third of the 211,000 Arkansans currently enrolled in Centene’s three plans. The Department of Human Services will transfer these enrollees to other eligible plans offered by BlueCross BlueShield.
Centene Corp., the parent company of several Arkansas health insurance plans, announced it will cease participation in the state's Medicaid expansion program, ARHOME, starting next year. This decision will impact about one-third of the 211,000 Arkansans currently enrolled in Centene's three plans, who will be transferred to other eligible plans. The move comes as Arkansas also prepares to reinstate Medicaid work requirements in 2027.
Centene Corp., the parent company of several Arkansas health insurance plans, will cease participation in the state's Medicaid expansion program, ARHOME, next year. This decision affects approximately one-third of the 211,000 Arkansans enrolled in ARHOME, who will be transferred to other eligible plans. The move comes as Arkansas prepares to reinstate Medicaid work requirements under the One Big Beautiful Bill Act.
Centene Corp. (CNC) shares fell by 2.67% to $66.05 on Monday, despite a generally favorable trading session for the broader stock market. The S&P 500 Index rose 0.72% and the Dow Jones Industrial Average gained 0.29%. This marked Centene's second consecutive day of losses.
Centene Corp., one of the two main providers of health insurance marketplace plans in Arkansas, announced its intention to withdraw from the state's Medicaid expansion program (ARHOME) starting in 2027. This move will affect approximately 70,000 Arkansans currently covered by Centene plans, who will be transitioned to other providers. Following Centene's departure, Arkansas Blue Cross and Blue Shield will be the sole participating company in the ARHOME program.
Centene Corp. plans to withdraw from Arkansas' ARHOME Medicaid expansion program in 2027 due to "funding challenges," leaving Arkansas Blue Cross and Blue Shield as the sole provider. Approximately 70,000 beneficiaries currently covered by Centene will be transitioned to other plans by the state. While exiting ARHOME, Centene will continue to offer Ambetter marketplace plans, Medicare, employer/group offerings, and participate in the PASSE program in Arkansas.
Centene Corp is re-evaluating its strategy and cost structure in response to the changing regulatory and reimbursement landscape within the US managed care sector. The company primarily focuses on government-sponsored health programs like Medicaid, Medicare, and Affordable Care Act marketplace plans, necessitating strict operational discipline and effective risk management. Centene's business model integrates health plan administration, provider network management, and care coordination to provide comprehensive health solutions.
Centene Corporation is enhancing its fraud prevention efforts through advanced analytics and AI-enabled tools to improve profitability in its government-sponsored healthcare businesses. This strategy, particularly effective in Medicaid, helped increase Q1 2026 adjusted EPS by 16.2% and improved the Medicaid health benefits ratio. These initiatives aim to strengthen cost controls and provide a competitive advantage, with competitors like UnitedHealth Group and Elevance Health also focusing on similar strategies.
Centene Corporation is enhancing its fraud prevention strategy by integrating advanced analytics and AI, aiming to improve profitability in its government-sponsored healthcare businesses. These efforts have already contributed to improved Medicaid margins and a raised adjusted EPS guidance for 2026. The company's focus on payment integrity and AI-driven analytics is expected to strengthen margin recovery and provide a competitive advantage, despite ongoing healthcare cost challenges.
Centene Corporation is enhancing its fraud, waste, and abuse prevention strategies, using advanced analytics and AI, to improve profitability in its government-sponsored healthcare businesses. These efforts have already contributed to improved Medicaid margins in Q1 2026, leading to raised EPS guidance for the year. Competitors like UnitedHealth Group and Elevance Health are also focusing on similar AI-driven payment integrity measures.
Ambetter health plans by Centene Corp. are a major product line on the Affordable Care Act (ACA) marketplaces, providing essential health benefits to millions of US families. The plans offer tiered options (bronze, silver, gold), digital tools, and focus on affordability for individuals and families without employer-sponsored coverage. Ambetter's presence across many states and its integration with ACA subsidies make it a significant player in the national health insurance landscape, affecting both consumers and Centene's financial performance.
Centene Corp. is a leading U.S. managed care company primarily serving Medicaid, Medicare, and Affordable Care Act marketplace members. The company emphasizes refining its portfolio and cost structure for sustainable growth within government-sponsored health programs, relying on operational efficiency and robust cost management strategies. Its business model is sensitive to U.S. healthcare policy and macroeconomic factors, which influence its membership and revenue, making ongoing adaptation crucial.
This article reviews the Q1 earnings for health insurance providers, highlighting Centene (NYSE:CNC) as a top performer. It discusses Centene's strong revenue and EPS beat, along with CVS Health's exceptional quarter. Conversely, Cencora (NYSE:COR) is noted for a weaker performance, while Clover Health (NASDAQ:CLOV) and Progyny (NASDAQ:PGNY) also showed strong results and growth.
Centene Corp. is a major player in the US managed care and government-sponsored health plan market, focusing on Medicaid, Medicare, and marketplace coverage. The company's financials are significantly influenced by membership growth, medical cost management, and policy changes. Centene uses care coordination, digital tools, and data analytics to optimize health outcomes and manage costs within its diverse health plans for individuals and employer groups.
Molina Healthcare specializes in government-sponsored health plans, primarily focusing on Medicaid, Medicare, and Affordable Care Act (ACA) marketplaces. The company operates as a managed care organization, contracting with state agencies to provide health benefits to vulnerable populations, emphasizing care coordination and cost control. Its business model, which includes a diversified portfolio of government-related health plans, is attractive to investors interested in publicly funded healthcare.
Centene Corp. is a major US managed care provider, focusing on government-sponsored healthcare programs like Medicaid and Medicare Advantage, serving millions of members. The company's business model revolves around coordinating and financing healthcare services for public entities, making its long-term prospects tied to government policies, demographic trends, and healthcare spending. Investors view Centene as an exposure to government-backed health programs, with its performance influenced by enrollment, cost control, and policy developments.
This article provides the latest SEC filing information and comprehensive financial data for Humana Inc. (HUM). It details various financial metrics such as market cap, income, sales, P/E ratios, dividend information, and performance indicators, alongside insider ownership and institutional transactions. The data reflects the company's financial health and stock performance as of July 2, 2024.
Centene's integrated healthcare model, combining government health plans with clinical, pharmacy, and community-based services, is expected to support its earnings growth. The company serves 26.3 million members, allowing for economies of scale, and is leveraging technology and data analytics to manage costs and improve outcomes. Despite regulatory challenges, Centene's investments in technology and clinical programs are set to drive margin recovery and sustainable long-term earnings growth.
Centene Corporation (CNC) is highlighted as a top momentum stock with a strong Relative Strength Index (RSI) of 67 and a high Quant rating of 4.94, despite historical trends suggesting July can be challenging for momentum stocks. The company, a significant player in the managed healthcare sector with a $33.75 billion market cap, has a GF Score™ of 74, indicating solid performance, particularly in profitability. However, investors are advised to exercise caution due to a low growth rank and significant insider selling, totaling $5.2 million over the past three months.
Centene Corporation's integrated healthcare model, combining government-sponsored health plans with coordinated clinical services, is supporting its earnings potential by effectively managing medical costs and improving health outcomes. The company is leveraging technology and data, including AI, to enhance operational capabilities and pricing decisions. Despite regulatory challenges, these efforts, along with its strong first-quarter 2026 performance and raised EPS guidance, position Centene for sustainable long-term growth, competing with giants like UnitedHealth and Elevance Health.
Molina Healthcare, a US-based managed care company, specializes in providing health insurance services through government programs like Medicaid and Medicare. The company's growth and profitability are closely tied to enrollment levels, effective management of medical costs relative to fixed payments, and the ever-changing policy environment surrounding public health coverage. Investors closely monitor these factors, along with regulatory developments and industry performance, to assess Molina Healthcare's financial health and future prospects.
This article from Investing.com announces the filing of a Form 4 for Centene Corp on July 1st. It also includes various financial market data such as indices, commodities, bonds, and stocks, along with trending news and market movers. The content primarily serves as a placeholder for a financial news update and features extensive financial data and news headlines.
